Pediatrix Medical price target raised to $18 from $15 at Truist

Truist analyst David MacDonald raised the firm’s price target on Pediatrix Medical (MD) to $18 from $15 and keeps a Hold rating on the shares. The company reported a solid Q4 result with both top/bottom-lines ahead and initial FY25 guidance that captured consensus estimates, the analyst tells investors in a research note. Pediatrix volumes were solid with payor mix an attractive tailwind and the management expecting solid trends into FY25 as labor costs continue to decelerate, even though they remain ahead of pre-2022 levels, the firm adds.